-
Report on Carcinogens : Carcinogen... 2004
Topics: Animals; Antineoplastic Agents; Carcinogenicity Tests; Carcinogens; Female; Government Regulation; Guidelines as Topic; Haplorhini; Humans; Male; Mice; Models, Biological; Occupational Exposure; Procarbazine; Rats; United States
PubMed: 21089949
DOI: No ID Found -
IARC Monographs on the Evaluation of... May 1981
Topics: Animals; Carcinogens; Chemical Phenomena; Chemistry; Female; Haplorhini; Humans; Male; Maternal-Fetal Exchange; Mice; Neoplasms, Experimental; Pregnancy; Procarbazine; Rats; Reproduction; Teratogens
PubMed: 6792050
DOI: No ID Found -
Report on Carcinogens : Carcinogen... 2002
Topics: Animals; Carcinogens; Environmental Exposure; Government Regulation; Humans; Procarbazine; United States
PubMed: 15334716
DOI: No ID Found -
Report on Carcinogens : Carcinogen... 2011
Topics: Animals; Antineoplastic Agents; Female; Humans; Hydrochloric Acid; Male; Mice; Neoplasms; Procarbazine; Rats
PubMed: 21863086
DOI: No ID Found -
Journal of Neurosurgery Mar 1974
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Ependymoma; Evaluation Studies as Topic; Female; Glioblastoma; Glioma; Glucocorticoids; Humans; Immunosuppression Therapy; Leukopenia; Male; Medulloblastoma; Middle Aged; Neoplasm Metastasis; Oligodendroglioma; Procarbazine; Radionuclide Imaging; Thrombocytopenia
PubMed: 4360491
DOI: 10.3171/jns.1974.40.3.0365 -
Pharmacotherapy May 2010Procarbazine hydrochloride is an oral alkylating agent primarily used as a component of chemotherapy regimens for Hodgkin's lymphoma, as well as in regimens for primary... (Review)
Review
Procarbazine hydrochloride is an oral alkylating agent primarily used as a component of chemotherapy regimens for Hodgkin's lymphoma, as well as in regimens for primary central nervous system lymphoma and high-grade gliomas. Although the prescribing information for procarbazine lists hepatic dysfunction as a potential adverse reaction, we found only one published report with a probable link between procarbazine and liver injury. We describe a 65-year-old man who developed liver injury due to procarbazine during salvage chemotherapy for non-Hodgkin's lymphoma. The patient had no preexisting liver disease, his lymphoma was without hepatic involvement, and no liver injury developed after initial chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Due to relapse of his non-Hodgkin's lymphoma, salvage chemotherapy with C-MOPP-R (cyclophosphamide, vincristine, procarbazine, prednisone, and rituximab) was administered, and the patient developed fever and aminotransferase level elevation during the second cycle. After discontinuation of all drug therapy, exclusion of other potential etiologies, and resolution of hepatic injury, the patient was rechallenged with procarbazine and again experienced fever with aminotransferase level elevation. His aminotransferase levels promptly returned to normal after discontinuation of procarbazine, and he experienced no further evidence of liver disease. Use of validated scoring systems of drug-induced liver injury indicated a definitive association between the patient's hepatic injury and procarbazine. Based on our experience with this patient, periodic assessment of hepatic function, as suggested in the package insert, is recommended in patients receiving procarbazine.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Drug Monitoring; Humans; Liver; Lymphoma, Non-Hodgkin; Male; Procarbazine; Salvage Therapy; Time Factors; Treatment Outcome
PubMed: 20412004
DOI: 10.1592/phco.30.5.540 -
Leukemia & Lymphoma Apr 2006Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma. It is most commonly used in the treatment of Hodgkin's disease. The use of...
Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma. It is most commonly used in the treatment of Hodgkin's disease. The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's lymphoma fell out of favor with the advent of CHOP. We report two patients with relapsed and/or refractory follicular lymphoma that achieved a complete and durable remission with a prolonged course of daily procarbazine.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Monoamine Oxidase Inhibitors; Procarbazine; Remission Induction; Stem Cell Transplantation
PubMed: 16690522
DOI: 10.1080/10428190600591517 -
Archives of Toxicology Aug 2023Mutagenicity testing is an essential component of health safety assessment. Duplex Sequencing (DS), an emerging high-accuracy DNA sequencing technology, may provide...
Mutagenicity testing is an essential component of health safety assessment. Duplex Sequencing (DS), an emerging high-accuracy DNA sequencing technology, may provide substantial advantages over conventional mutagenicity assays. DS could be used to eliminate reliance on standalone reporter assays and provide mechanistic information alongside mutation frequency (MF) data. However, the performance of DS must be thoroughly assessed before it can be routinely implemented for standard testing. We used DS to study spontaneous and procarbazine (PRC)-induced mutations in the bone marrow (BM) of MutaMouse males across a panel of 20 diverse genomic targets. Mice were exposed to 0, 6.25, 12.5, or 25 mg/kg-bw/day for 28 days by oral gavage and BM sampled 42 days post-exposure. Results were compared with those obtained using the conventional lacZ viral plaque assay on the same samples. DS detected significant increases in mutation frequencies and changes to mutation spectra at all PRC doses. Low intra-group variability within DS samples allowed for detection of increases at lower doses than the lacZ assay. While the lacZ assay initially yielded a higher fold-change in mutant frequency than DS, inclusion of clonal mutations in DS mutation frequencies reduced this discrepancy. Power analyses suggested that three animals per dose group and 500 million duplex base pairs per sample is sufficient to detect a 1.5-fold increase in mutations with > 80% power. Overall, we demonstrate several advantages of DS over classical mutagenicity assays and provide data to support efforts to identify optimal study designs for the application of DS as a regulatory test.
Topics: Male; Mice; Animals; Procarbazine; Mutation Rate; Bone Marrow; Mutagens; Mutation; Mutagenicity Tests; Mice, Transgenic; Lac Operon
PubMed: 37341741
DOI: 10.1007/s00204-023-03527-y -
Annals of Internal Medicine Dec 1974
Review
Topics: Animals; Bone Neoplasms; Carcinogens; Carcinoma; Drug Evaluation; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myeloproliferative Disorders; Neoplasms; Polycythemia Vera; Procarbazine
PubMed: 4611297
DOI: 10.7326/0003-4819-81-6-795 -
Thorax Mar 1984
Topics: Adult; Alveolitis, Extrinsic Allergic; Humans; Male; Procarbazine
PubMed: 6710430
DOI: 10.1136/thx.39.3.206